Underuse of Oral Anticoagulants and ...
Type de document :
Article dans une revue scientifique
PMID :
URL permanente :
Titre :
Underuse of Oral Anticoagulants and Inappropriate Prescription of Antiplatelet Therapy in Older Inpatients with Atrial Fibrillation
Auteur(s) :
Averlant, Lorette [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Ficheur, Gregoire [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Ferret, Laurie [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Boule, Stephane [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Puisieux, Francois [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Luyckx, Michel [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - EA 7365
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Soula, Julien [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Georges, Alexandre [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Beuscart, Regis [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Chazard, Emmanuel [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
BEUSCART, Jean-Baptiste [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Ficheur, Gregoire [Auteur]

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Ferret, Laurie [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Boule, Stephane [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Puisieux, Francois [Auteur]

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Luyckx, Michel [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - EA 7365
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Soula, Julien [Auteur]

Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Georges, Alexandre [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Beuscart, Regis [Auteur]

Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Chazard, Emmanuel [Auteur]

Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
BEUSCART, Jean-Baptiste [Auteur]

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Titre de la revue :
Drugs and Aging
Nom court de la revue :
Drugs Aging
Numéro :
34
Pagination :
701-710
Date de publication :
2017
ISSN :
1170-229X
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
BACKGROUND: Several studies have shown that the prescription of antiplatelet therapy (APT) is associated with an increased risk of oral anticoagulant (OAC) underuse in patients aged 75 years and over with atrial fibrillation ...
Lire la suite >BACKGROUND: Several studies have shown that the prescription of antiplatelet therapy (APT) is associated with an increased risk of oral anticoagulant (OAC) underuse in patients aged 75 years and over with atrial fibrillation (AF). An associated atheromatous disease may be the underlying reason for APT prescription. The objective of the study was to determine whether the association between underuse of OAC and APT prescription was explained by the presence of an atheromatous disease. METHODS AND RESULTS: We performed a retrospective, observational, single-centre study between 2009 and 2013 based on administrative data. Patients aged 75 years and over with non-valvular AF were identified in a database of 72,090 hospital stays. Prescriptions of anti-thrombotic medications and their association with the presence of atheromatous disease were evaluated by the mean of a logistic regression. A total of 2034 hospital stays were included (mean age 84.3 ± 5.2 years). The overall prevalence of known atheromatous disease was 25.9%. OAC underuse was observed in 58.5% of the stays. In multivariable analysis, the prescription of an APT was associated with an increased risk of OAC underuse [odds ratio (OR) 6.85; 95% confidence interval (CI) 5.50-8.58], independently of the presence of a concomitant known atheromatous disease (OR 0.78; 95% CI 0.60-1.01). Among the 692 stays with APT monotherapy (34.0%), 232 (33.5%) displayed an atheromatous disease. CONCLUSIONS: The underuse of OAC is associated with the prescription of APT in older patients with AF, regardless of the presence or absence of known atheromatous disease. Our results suggest that APT is often inappropriately prescribed instead of OAC.Lire moins >
Lire la suite >BACKGROUND: Several studies have shown that the prescription of antiplatelet therapy (APT) is associated with an increased risk of oral anticoagulant (OAC) underuse in patients aged 75 years and over with atrial fibrillation (AF). An associated atheromatous disease may be the underlying reason for APT prescription. The objective of the study was to determine whether the association between underuse of OAC and APT prescription was explained by the presence of an atheromatous disease. METHODS AND RESULTS: We performed a retrospective, observational, single-centre study between 2009 and 2013 based on administrative data. Patients aged 75 years and over with non-valvular AF were identified in a database of 72,090 hospital stays. Prescriptions of anti-thrombotic medications and their association with the presence of atheromatous disease were evaluated by the mean of a logistic regression. A total of 2034 hospital stays were included (mean age 84.3 ± 5.2 years). The overall prevalence of known atheromatous disease was 25.9%. OAC underuse was observed in 58.5% of the stays. In multivariable analysis, the prescription of an APT was associated with an increased risk of OAC underuse [odds ratio (OR) 6.85; 95% confidence interval (CI) 5.50-8.58], independently of the presence of a concomitant known atheromatous disease (OR 0.78; 95% CI 0.60-1.01). Among the 692 stays with APT monotherapy (34.0%), 232 (33.5%) displayed an atheromatous disease. CONCLUSIONS: The underuse of OAC is associated with the prescription of APT in older patients with AF, regardless of the presence or absence of known atheromatous disease. Our results suggest that APT is often inappropriately prescribed instead of OAC.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Équipe(s) de recherche :
Innovation/évaluation des médicaments injectables
Date de dépôt :
2019-02-26T17:07:07Z
2021-12-15T09:37:31Z
2021-12-15T09:37:31Z